A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma

Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogs

Brian W. Metcalf, Philippe Bey, Charles Danzin et al. · Journal of the American Chemical Society · 1978 · 1K citations

Life Sciences, Pharmacology, Biocatalysis +16

Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs

Sydney E. Salmon, Anne W. Hamburger, B Soehnlen et al. · New England Journal of Medicine · 1978 · 974 citations

Medicine, Oncology, Pharmacology +16

Anti-proliferative properties of DL-α-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase

Pierre S. Mamont, Marie-Christine Duchesne, Jeffrey Grove et al. · Biochemical and Biophysical Research Communications · 1978 · 400 citations

Life Sciences, Biochemistry, Pharmacology +11

DTIC (NSC-45388) in malignant melanoma: a perspective.

Comis Rl · PubMed · 1976 · 165 citations

Veterinary Medicine, Dermatology, Oncology +12

Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.

Martin D. Abeloff, M Slavík, G D Luk et al. · Journal of Clinical Oncology · 1984 · 146 citations

Medicine, Oncology, Pharmacology +15